Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a loss between 75 million to 58 million yuan, representing a year-on-year decrease of 110.21% to 171.83% [1] Financial Performance - The anticipated net profit loss, excluding non-recurring gains and losses, is estimated to be between 76 million to 59 million yuan, reflecting a year-on-year decline of 109.10% to 169.34% [1] - The financial data will be detailed in the 2025 annual report [1] Reasons for Performance Change - The primary reasons for the performance change include a slight decrease in market prices for certain products, the annual solidification of new projects leading to incomplete capacity release, and higher unit costs during the initial phase of new product launches [1] - Increased research and development expenses due to ongoing investments in new product development have contributed to the financial strain [1] - Interest expenses have risen as capitalized interest on convertible bonds and project-specific loans ceased following the solidification of fundraising projects [1]
共同药业：预计2025年亏损7500万元至5800万元，同比下降110.21%至171.83%